Alpha 2.0
Login Register
» Authors » Garrett Frampton

Garrett Frampton

Explore the profile of Garrett Frampton including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 2077
Followers 0
Related Specialties
Oncology
Allergy & Immunology
Pharmacology
Top 10 Co-Authors
Jeffrey S Ross
Vincent A Miller
David Fabrizio
Razelle Kurzrock
Siraj M Ali
Philip J Stephens
Aaron M Goodman
Jo-Anne Vergilio
Vincent Miller
Julia A Elvin
Published In
Oncologist
J Immunother Cancer
Clin Cancer Res
JCO Precis Oncol
Oncotarget
Affiliations
Soon will be listed here.
Recent Articles
1.
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
Florou V, Floudas C, Maoz A, Naqash A, Norton C, Tan A, et al.
J Immunother Cancer . 2023 Aug; 11(8). PMID: 37586768
Background: Pembrolizumab is FDA approved for tumors with tumor mutational burden (TMB) of ≥10 mutations/megabase (mut/Mb). However, the response to immune checkpoint inhibitors (ICI) varies significantly among cancer histologies. We...
2.
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
Chen K, Madison R, Moore J, Jin D, Fleischmann Z, Newberg J, et al.
Oncologist . 2023 Jun; 28(8):691-698. PMID: 37354528
Background: Pancreatic cancer (PC) represents an aggressive disease with median overall survival (OS) of less than 1 year in the front-line setting. FOLFIRINOX and gemcitabine and paclitaxel (GP) are standard...
3.
Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board
Green M, Watson C, Tait S, He J, Pavlick D, Frampton G, et al.
Oncologist . 2022 Aug; 28(1):33-39. PMID: 35962742
Objective: The majority of tumor sequencing currently performed on cancer patients does not include a matched normal control, and in cases where germline testing is performed, it is usually run...
4.
PARP Inhibitor Insensitivity to Monoallelic Mutations in Microsatellite Instability-High Cancers
Sokol E, Jin D, Fine A, Trabucco S, Maund S, Frampton G, et al.
JCO Precis Oncol . 2022 Jun; 6:e2100531. PMID: 35772050
Purpose: To examine the overlap of homologous recombination deficiency (HRD) and microsatellite instability high (MSI-H) status, and to dissect driver versus bystander status of mutations () in this context. Methods:...
5.
Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers
Serebriiskii I, Pavlov V, Tricarico R, Andrianov G, Nicolas E, Parker M, et al.
Nat Commun . 2022 Mar; 13(1):1618. PMID: 35338148
Loss of expression or activity of the tumor suppressor PTEN acts similarly to an activating mutation in the oncogene PIK3CA in elevating intracellular levels of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), inducing signaling...
6.
Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma
Zhang L, Hamdani O, Gjoerup O, Cho-Phan C, Snider J, Castellanos E, et al.
JCO Precis Oncol . 2022 Jan; 6:e2100330. PMID: 35050711
Purpose: Human epidermal growth factor receptor 2 (HER2) overexpression or amplification (amp) are biomarkers for approved anti-HER2 therapies. amp may better predict response compared with immunohistochemistry or in situ hybridization,...
7.
Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers
Pham T, Goodman A, Sivakumar S, Frampton G, Kurzrock R
Genome Med . 2021 Oct; 13(1):159. PMID: 34641956
Background: Tumor mutational burden (TMB) may be a predictive biomarker of immune checkpoint inhibitor (ICI) responsiveness. Genomic landscape heterogeneity is a well-established cancer feature. Molecular characteristics may differ even within...
8.
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Negrao M, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al.
J Immunother Cancer . 2021 Aug; 9(8). PMID: 34376553
Background: Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB)...
9.
Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry
Huang R, Severson E, Haberberger J, Duncan D, Hemmerich A, Edgerly C, et al.
Pathol Oncol Res . 2021 Jul; 27:592997. PMID: 34257540
Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC) given the expanding number of standard-of-care therapies that require companion...
10.
Pan-cancer landscape of (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression
Huang R, Murugesan K, Montesion M, Pavlick D, Mata D, Hiemenz M, et al.
J Immunother Cancer . 2021 May; 9(5). PMID: 33972391
Introduction: Several studies have shown clinical outcomes data that support the use of ) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present...